For over a century, scientists have envisioned developing a vaccine that would unleash the power of the immune system to cure cancer. However, these efforts have been a great disappointment.
Scientists first approached the problem with great optimism with the idea of designing vaccines against cancer much in the same way vaccines were designed to wipe out serious diseases like Polio and measles.
I am a board certified Emergency Physician who participated in Immunovative Therapies Ltd.’s Phase I/II trial in Carlsbad, California. I was responsible for onsite patient safety and functioned as a co-investigator in this first-in-human clinical trial in which AlloStim® administration was combined with cryoablation of a selected tumor lesion. The results of this study, along with three-year follow-up data, are currently being prepared for submission to a peer-reviewed journal. An abstract, entitled “Response of HER2+ breast cancer patients to allogeneic cell immunotherapy” was presented at the 2012 ASCO Annual Meeting and describes the responses of the trial’s breast cancer patients at the one year follow-up
Dr. Michael Har-Noy of Hadassah-Hebrew University Medical Center and the founder of Immunovative Therapies, Ltd. will be a key-note speaker at Immunotherapy World 2016. He has listed his TOP 10 issues that confront design of therapeutic cancer vaccines. In his address at the conference, Dr. Har-Noy will discuss a “unified field” approach to cancer vaccine design which can address all the listed issues.